Corcept therapeutics inc (CORT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Cash flows from operating activities:
Net income

30,065

29,381

26,340

20,186

18,274

22,008

17,747

18,196

17,459

98,330

13,757

12,647

4,388

4,597

2,585

977

-19

959

-601

-1,936

-4,830

-3,895

-6,007

-7,551

-13,930

-11,124

-10,906

-11,897

-12,084

-11,124

-8,294

-7,596

-11,034

Adjustments to reconcile net income to net cash generated from operations:
Stock-based compensation

7,918

7,610

7,271

7,736

6,696

6,266

6,510

6,017

4,954

3,832

3,623

3,205

2,701

1,957

1,831

1,657

1,613

1,493

1,543

1,568

1,409

1,387

1,211

1,225

1,378

1,313

1,308

1,265

1,310

1,046

993

883

2,388

Accretion of interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

455

523

584

652

697

737

762

804

895

935

1,044

1,070

1,133

1,092

1,115

-

-

-

-

Depreciation and amortization of property and equipment

-

-

-

-

-

-

-

-

-

0

3

6

5

5

5

6

5

2

9

5

6

6

9

6

8

8

8

8

11

-

-

-

-

Deferred income taxes

5,095

5,146

5,897

4,908

926

3,465

4,960

2,473

3,169

-76,703

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of interest income

177

-3,151

360

419

634

-2,741

474

744

-198

0

37

149

270

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income taxes

-

-

-

-

-

-

-

-

-54

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization of property and equipment

238

229

211

167

96

73

58

57

48

48

36

9

13

15

21

24

27

28

30

57

40

37

39

37

28

21

20

19

14

13

6

5

3

Non-cash amortization of right-of-use asset

364

332

364

359

413

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Trade receivables

6,756

-2,477

2,631

556

1,630

-1,772

-9,344

11,443

1,961

3,428

2,368

290

-646

1,624

-1,065

2,549

531

276

994

650

967

588

521

303

494

409

164

-288

586

-

-

-

-

Other receivable

-

-

-

-

-

0

0

-20

-12,876

-69

12,965

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

-1,328

390

-889

2,453

-910

3,433

2,275

2,661

-590

1,918

-791

-409

1,544

-143

1,213

-98

-290

-112

-277

-169

-257

-211

-132

183

-89

-9

11

868

13

2,186

40

2,381

56

Prepaid expenses and other current assets

-351

-1,754

1,596

461

-1,999

3,465

696

275

635

-417

559

728

-165

643

-105

320

464

-538

-61

619

-819

-328

-397

713

543

-94

203

229

-48

-180

192

506

-38

Other assets

-7

3,298

0

75

25

-3

0

-20

23

26

-25

0

25

0

0

0

0

-4

3

-2

10

-1

3

-3

-9

1

0

0

3

-8

-231

188

40

Accounts payable

-2,600

1,689

-1,125

-2,252

953

-5,732

7,557

-1,455

-759

2,367

4,138

-2,179

1,963

-2,019

2,228

-1

757

-415

-620

1,324

-850

-74

-635

-1,071

1,285

44

-696

770

-1,541

2,230

-2,661

2,151

-1,527

Accrued clinical expenses

1,461

2,356

-1,597

1,181

1,016

-1,871

-5

1,911

1,239

355

381

50

-6

-308

812

-131

-77

562

117

-866

1,022

60

-1,367

-1,737

92

1,325

919

461

-260

238

-35

-141

137

Accrued and other liabilities

-3,676

1,690

5,142

-2,393

-4,956

2,895

1,779

2,753

-2,383

1,247

4,026

2,288

985

2,079

1,041

1,306

1,270

425

325

88

543

337

-85

353

-30

14

-28

-106

375

-

-

-

-

Operating lease liabilities

-349

-344

-378

-373

-357

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-158

79

42

-18

22

-17

6

15

4

-30

18

-39

60

-

-

-

-

Accrued compensation and other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

183

210

-66

Net cash provided by operating activities

33,269

48,454

38,427

25,555

23,681

21,519

44,505

15,211

34,430

24,883

10,925

15,566

9,561

4,569

8,935

1,590

3,297

4,163

883

-139

-1,777

-1,403

-5,929

-8,984

-11,060

-7,666

-8,602

-9,236

-11,554

-8,742

-9,229

-7,892

-10,157

Cash flows from investing activities:
Purchases of property and equipment

42

135

286

410

257

113

45

63

77

29

82

198

110

75

90

7

22

-17

0

0

34

0

16

48

110

40

65

4

18

58

52

34

7

Proceeds from maturities of marketable securities

68,245

13,850

38,300

59,320

70,825

54,155

48,200

23,650

16,650

17,476

10,674

1,800

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

48,469

75,704

92,330

60,066

70,935

55,799

81,661

44,798

50,866

44,895

22,239

16,550

19,303

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

19,734

-61,989

-54,316

-1,156

-367

-1,757

-33,506

-21,211

-34,293

-27,448

-11,647

-14,948

-19,413

-75

-90

-7

-22

17

0

0

-34

0

-16

-48

-110

-40

-65

-4

-18

-58

-52

-34

-7

Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of options, net of issuance costs

480

1,776

2,696

1,512

2,435

2,722

634

4,044

1,922

2,567

2,772

718

1,124

3,610

1,267

2,731

75

-

1,009

1,322

17,381

-

27

405

906

-

-

-

-

-85

46,150

198

13,156

Repurchase of common stock

275

0

0

17,420

13,555

14,753

8,904

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments related to debt obligation

-

-

-

-

-

-

-

-

-

0

4,613

5,689

4,832

4,433

4,036

3,269

3,041

2,764

2,490

2,088

1,865

1,568

1,276

1,017

995

-

-

-

-

-

-

-

-

Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercise

0

1,920

0

0

4,169

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

205

-144

2,696

-15,908

-15,289

-12,031

-8,270

4,044

1,922

2,567

-1,841

-4,971

-3,708

-823

-2,769

-538

-2,966

-195

-1,481

-766

15,516

-1,129

-1,249

-612

-89

-

-

-

-

204

76,010

198

13,156

Supplemental disclosure:
Net increase in cash and cash equivalents

53,208

-13,679

-13,193

8,491

8,025

7,731

2,729

-1,956

2,059

2

-2,563

-4,353

-13,560

3,671

6,076

1,045

309

3,985

-598

-905

13,705

-2,532

-7,194

-9,644

-11,259

-8,298

-9,045

-9,240

-11,572

-8,596

66,729

-7,728

2,992

Supplemental disclosure:
Exercise price of shares tendered in net settlement of cashless option exercise

0

1,052

0

0

931

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Recognition of right-of-use asset and lease liability

0

3,035

0

0

1,878

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-